2.
Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, Eckloff BW, Wieben ED, Wu Y, Cunningham JM, Nagorney DM, Gilbert JA, Ames MM, Beutler AS. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123(6):2502–8. doi:
10.1172/JCI67963. 67963 [pii].
CrossRefPubMedPubMedCentral
3.
Caplin M. Phase III trial results favour lanreotide therapy. In: Patients with gastroenteropancreatic neuro-endocrine tumours. Amsterdam: European Society of Medical Oncology (ESMO); 2013.
4.
Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Manzano Mozo JL, Sevilla I, Duran I, Salazar R. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013;49(18):3780–7. doi:
10.1016/j.ejca.2013.06.042.
CrossRefPubMed
5.
Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2963–8. doi:JCO.2011.40.3147 [pii]
10.1200/JCO.2011.40.3147.
CrossRef
6.
Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22(1):1–9. doi:
10.1530/ERC-14-0360.
CrossRefPubMed
7.
Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015;22(3):431–41. doi:
10.1530/ERC-15-0002.
CrossRefPubMedPubMedCentral
8.
de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):451–8.
CrossRef
9.
Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95(9):1148–54. doi:6603419 [pii]
10.1038/sj.bjc.6603419.
CrossRefPubMedPubMedCentral
11.
Feyrter F. Über diffuse endocrine epitheliale Organe. Leipzig: Barth; 1938.
12.
Grande E, Capdevila J, Castellano D, Teule A, Duran I, Fuster J, Sevilla I, Escudero P, Sastre J, Garcia-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Diez JJ, Carrato A, Garcia-Carbonero R. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) dagger. Ann Oncol Off J Eur Soc Med Oncol. 2015. doi:
10.1093/annonc/mdv252.
13.
Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman E. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(18):Suppl 4043.
14.
Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(14):1551–6. doi:
10.1200/JCO.2014.56.2082.
CrossRef
15.
Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(18):Suppl 4504.
16.
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz Jr LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203. doi:science.1200609 [pii]
10.1126/science.1200609.
CrossRefPubMedPubMedCentral
17.
Kulke M, Niedzwiecki D, Foster N, Briant Fruth B, Kunz P, Kennecke H, Wolin E, Venook A. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E + B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:Suppl; abstr 4005.
18.
Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(20):3403–10. doi:26/20/3403 [pii]
10.1200/JCO.2007.15.9020.
CrossRef
19.
Kunz PL, Kuo T, Zhan JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford M, Balise RR, Fisher GA. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol. 2010;28:15s Suppl; abstr 4104.
20.
Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–6.
CrossRefPubMed
21.
Kvols LK, Oberg KE, O’Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–66. doi:
10.1530/ERC-11-0367.
22.
Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):173–85, ix. doi:
10.1016/j.ecl.2010.12.003.
CrossRefPubMed
23.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246–54.
CrossRefPubMed
24.
Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg. 1993;17(4):504–10.
CrossRefPubMed
25.
Maurer R, Reubi JC. Somatostatin receptors. JAMA. 1985;253(18):2741.
CrossRefPubMed
27.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12. doi:S0140-6736(11)61742-X [pii]
10.1016/S0140-6736(11)61742-X.
CrossRefPubMed
28.
Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16(6):695–703. doi:
10.1016/S1470-2045(15)70136-1.
CrossRefPubMedPubMedCentral
29.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. doi:
10.1056/NEJMoa1003825.
CrossRefPubMed
30.
Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol. 1997;11(8):1062–9.
CrossRefPubMed
31.
Reichlin S. Somatostatin. N Engl J Med. 1983;309(24):1495–501.
CrossRefPubMed
32.
Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4656–63.
CrossRef
33.
Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155–62. doi:
10.1038/nrm3757.
CrossRefPubMed
34.
Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend Jr CM, Evers BM. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128(5):1045–56. doi:
10.1002/ijc.25441.
CrossRefPubMedPubMedCentral
35.
Stilling GA, Zhang H, Ruebel KH, Leontovich AA, Jin L, Tanizaki Y, Zhang S, Erickson LA, Hobday T, Lloyd RV. Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors. Endocr Pathol. 2007;18(4):223–32. doi:
10.1007/s12022-007-9001-3.
CrossRefPubMed
36.
Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16(24):2963–70.
CrossRefPubMedPubMedCentral
37.
Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013;20(3):383–90. doi:
10.1530/ERC-12-0390.
CrossRefPubMedPubMedCentral
38.
Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32(2):133–8.
CrossRefPubMed
39.
Venook AP, Ko AH, Tempero MA, Uy J, Weber T, Korn M, EK B. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol. 2008;26:15_Suppl 15545, 26(15):Suppl 15545.
40.
Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, Weissman H, Palmer DH, Vora J, Pritchard DM, Cuthbertson DJ. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108(7):1440–8. doi:
10.1038/bjc.2013.103.
CrossRefPubMedPubMedCentral
41.
Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2(12):999–1017.
CrossRefPubMed
42.
Wolin E, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse M, Tomassetti P, Weber M, Fogelman D, Ramage J, Poon D, Huang J, Hudson M, Zhi X, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Oberg K. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors with disease-related symptoms inadequately controlled by somatostatin analogs. J Clin Oncol Off J Am Soc Clin Oncol. 2013;(31):Suppl;abstr 4031.
43.
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84.
CrossRefPubMed
44.
Yao J, Guthrie K, Moran C, Strosberg J, Kulke M, Chan J, LoConte N, McWilliams R, Wolin E, Mattar B, McDonough S, Chen H, Blanke C, Hochster H. SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:Suppl;abstr 4004.
45.
Yao J, Phan A, Fogelman D, Ng C, Jacobs C, Dagohoy C, Leary C, Hess K. Randomized run-in study of bevacizumab and everolimus in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(15):Suppl 4002.
46.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):69–76. doi:JCO.2009.24.2669 [pii]
10.1200/JCO.2009.24.2669.
CrossRef
47.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(8):1316–23.
CrossRef
48.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. doi:
10.1056/NEJMoa1009290.
CrossRefPubMedPubMedCentral